Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.

Published in: Expert opinion on drug delivery (2020)

There are no appreciable differences between TCZ-SC and TCZ-IV in clinical practice. Thus, TCZ-SC is an attractive option for RA patients.

Keyphrases